As of May 29, 2025, Abbvie Inc (ABBV) reports a ROE (Return on Equity) of 128.66%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Abbvie Inc's ROE (Return on Equity)
Over recent years, Abbvie Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 128.66% |
| 2023-12-31 | 46.94% |
| 2022-12-31 | 68.60% |
| 2021-12-31 | 74.91% |
| 2020-12-31 | 35.30% |
This slight downward trend highlights how Abbvie Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Abbvie Inc's ROE (Return on Equity) to Peers
To better understand Abbvie Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Abbvie Inc (ABBV) | 128.66% |
| Sorrento Therapeutics Inc (SRNE) | 3079.57% |
| Agios Pharmaceuticals Inc (AGIO) | 43.72% |
| PTC Therapeutics Inc (PTCT) | 33.08% |
| ACADIA Pharmaceuticals Inc (ACAD) | 30.90% |
| Exelixis Inc (EXEL) | 23.23% |
Compared to its competitors, Abbvie Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.